However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people ...

Merck & Co. Inc. closed 42.70% short of its 52-week high of $134.63, which the company reached on June 25th.

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg. Click here to find out ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

Merck stock slumps 38% YoY; Q1 earnings could be a pivotal turning point. Analysts see 29% upside despite bearish technicals and weak recent performance. Unlock your all-in-one trading dashboard ...